119757-57-2

Basic information

• Product Name: (E/E)-1-[4-(2-Chloroethoxy)phenyl]-1-(4-hydroxyphenyl)-2-phenyl-1-butene
• Synonyms: 4-[1-[4-(2-chloroethoxy)phenyl]-2-phenyl-1-butenyl]-phenol;(E/Z)-1-[4-(2-Chloroethoxy)phenyl]-1-(4-hydroxyphenyl)-2-phenyl-1-butene
• CAS NO: 119757-57-2
• Molecular Formula: C24H23ClO2
• Molecular Weight: 378.89
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 119757-57-2.mol

Chemical Properties

• Melting Point: 125-128°C
• Boiling Point: 509°C at 760 mmHg
• Flash Point: 261.6°C
• Appearance: /
• Density: 1.163g/cm³
• Vapor Pressure: 5.55E-11mmHg at 25°C
• Refractive Index: 1.607
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: (E/E)-1-[4-(2-Chloroethoxy)phenyl]-1-(4-hydroxyphenyl)-2-phenyl-1-butene(CAS DataBase Reference)
• NIST Chemistry Reference: (E/E)-1-[4-(2-Chloroethoxy)phenyl]-1-(4-hydroxyphenyl)-2-phenyl-1-butene(119757-57-2)
• EPA Substance Registry System: (E/E)-1-[4-(2-Chloroethoxy)phenyl]-1-(4-hydroxyphenyl)-2-phenyl-1-butene(119757-57-2)

Safety Data

• Hazardous Substances Data: 119757-57-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(E/E)-1-[4-(2-Chloroethoxy)phenyl]-1-(4-hydroxyphenyl)-2-phenyl-1-butene is used as an intermediate in the synthesis of a metabolite of the anti-cancer drug Tamoxifen. Its role in the production process is crucial for creating the active components of the medication, which can help in the treatment of various types of cancer.
As a chemical intermediate, (E/E)-1-[4-(2-Chloroethoxy)phenyl]-1-(4-hydroxyphenyl)-2-phenyl-1-butene plays a significant role in the development and manufacturing of pharmaceutical products, particularly in the area of oncology. Its unique structure and properties make it a valuable component in the synthesis of compounds that can target and combat cancer cells effectively.

InChI:InChI=1/C24H23ClO2/c1-2-23(18-6-4-3-5-7-18)24(19-8-12-21(26)13-9-19)20-10-14-22(15-11-20)27-17-16-25/h3-15,26H,2,16-17H2,1H3/b24-23+

Upstream product

• 1032008-64-2 C₂₉H₃₃ClO₄ 
• 90-27-7 2-Phenylbutyric acid 
• 103628-22-4 1--2-phenyl-butan-1-one 
• 36854-57-6 2-Phenylbutyryl chloride 
• 114031-67-3 [4-(4-hydroxybenzoyl)phenyl]-2,2-dimethyl propanoate 
• 36603-49-3 4-(tetrahydropyran-2'-yloxy)-1-bromobenzene 
• 108-95-2 phenol 
• 622-86-6 2-chloroethoxybenzene 
• 1215295-57-0 (4-(2-chloroethoxy)phenyl)(4-hydroxyphenyl)methanone 
• 93-55-0 1-phenyl-propan-1-one 

Downstream Products

• 103628-14-4 (Z)-1-<4-(2-chloroethoxy)phenyl>-1-<4-<2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenoxy>phenyl>-2-phenyl-1-butene 
• 103628-15-5 (E)-1-<4-(2-chloroethoxy)phenyl>-1-<4-<2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenoxy>phenyl>-2-phenyl-1-butene 
• 174592-47-3 trans 4-hydroxytamoxifen 
• 114828-90-9 trans-Endoxifen 
• 1350660-46-6 (E/Z)-4-(1-{4-[2-(hexylamino)ethoxy]phenyl}-2-phenylbut-1-en-1-yl)phenol 
• 1331643-32-3 Tam-N₃ 

Relevant articles and documents

High affinity fluorescent ligands for the estrogen receptor

Fluorescent binders of the estrogen receptor (ER) are used in binding assays and in detection or imaging studies. However, fluorescence labelling of ER ligands usually leads to substantial decreases in binding affinity. In this study, we describe the deve

Design and synthesis of norendoxifen analogues with dual aromatase inhibitory and estrogen receptor modulatory activities

Both selective estrogen receptor modulators and aromatase inhibitors are widely used for the treatment of breast cancer. Compounds with both aromatase inhibitory and estrogen receptor modulatory activities could have special advantages for treatment of br

Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator

We designed and synthesized an estrogen receptor (ER) down-regulator (5), which is a derivative of tamoxifen with a long alkyl side chain. Compound 5 effectively reduced ER protein levels in MCF-7 cells and had an antagonistic effect.

Endoxifen is a new potent inhibitor of PKC: A potential therapeutic agent for bipolar disorder

Protein kinase C (PKC) plays a major role in regulation of both pre and postsynaptic neurotransmission. Excessive activation of PKC results in symptoms related to bipolar disorder. Tamoxifen, a widely used breast cancer drug is known to inhibit PKC and demonstrate antimanic properties in human. We describe herein the synthesis of endoxifen, a tamoxifen active metabolite and compared its PKC inhibitory activity with that of tamoxifen. Endoxifen exhibited fourfold higher potency compared to tamoxifen.

ENDOXIFEN METHODS AND COMPOSITIONS

The present invention provides compositions containing endoxifen, formulations and liposomes of endoxifen, methods of preparation of such agents and formulations, and use of such agents and formulations for the treatment of breast cancer and other breast

Triphenylethylenes, process for their production, pharmaceutical preparations that contain these triphenylethylenes as well as their use for the production of pharmaceutical agents

This invention describes the new triphenylethylenes of general formula I STR1 in which n means an integer from 1 to 10, R' means a sulfur-containing organic radical, R" means a hydrogen atom, an iodine atom or a hydroxy groups, E means a hydrogen atom, G

The Use of the Perfluorotolyl Protecting Group in the Synthesis of Pure Z and E Isomers of 4-Hydroxytamoxifen -1-(4-hydroxyphenyl)-2-phenyl-1-butene>

The perfluorotolyl protecting group has been used in the synthesis of pure Z and E isomers of 4-hydroxytamoxifen (4a), a potent metabolite of the anticancer drug, tamoxifen (1a). 4-(Perfluorotolyloxy)phenyl magnesium bromide underwent addition to the carbonyl group of the easily prepared versatile ketone, 1--2-phenyl-1-butanone (7), without affecting the chloroethoxy group.Acid catalysed dehydration of the resulting carbinol gave a 1:1 mixture of isomeric ethers, (6a) and (6b), that were easily separated by chromatography and respectively converted to the Z (4a) and E (4b) isomers of 4-hydroxytamoxifen.The property of the perfluorotolyl function in enabling the separation of geometrical isomers is attributed to a combination of its lipophilicity and electron withdrawal.